VivoSim Labs (FRA:4OR) Moat Score: 1/10 (As of Jun. 24, 2026)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.13
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Moat Score?

VivoSim Labs FRA:4OR 39 Moat Score is 1 as of Jun. 24, 2026. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review. Among 1,405 Biotechnology companies, VivoSim Labs ranks worse than 52.67% on this metric.

VivoSim Labs has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

VivoSim Labs has No Moat: VivoSim Labs Inc has minimal competitive advantages. The company is in an early stage with limited market presence, no significant intellectual property, and lacks customer loyalty or network effects. Its current position does not support a sustainable economic moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes VivoSim Labs might have No Moat - Very weak/transient advantages.

VivoSim Labs  (FRA:4OR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

VivoSim Labs Moat Score Related Terms

FRA:4OR vs AZTR, GRI, BIXT: Moat Score Comparison

For the Biotechnology subindustry, VivoSim Labs's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VivoSim Labs Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Moat Score distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Moat Score falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
VivoSim Labs (FRA:4OR) has a Moat Score of 1 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, VivoSim Labs ranks #740 out of 1405 companies in the Biotechnology industry, placing it in the top 52.7%.
Is VivoSim Labs' Moat Score too high?
VivoSim Labs' current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. VivoSim Labs' value of 1 is 50% below this industry median. Based on the distribution chart, VivoSim Labs ranks #740 out of 1405 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Moat Score compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #740 out of 1405 companies for Moat Score. This places VivoSim Labs in the lower half of its industry. The industry median Moat Score is 2.00. VivoSim Labs' value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Moat Score of 1. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Moat Score is 1 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.

Key valuation signals for FRA:4OR:

  • Moat Score: 1
  • GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
  • GF Score™: 39/100 with 4 warning signs
  • Industry Position: 50% below the Biotechnology median (#740 of 1405)

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.13
GF Value